Welcome to the international HTA database

Showing [21936 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Relationship between volume of services and quality of treatment outcome for heart transplantations in adults - Rapid Report]
2020	NIHR Health Technology Assessment programme	Two speeds of increasing milk feeds for very preterm or very low-birthweight infants: the SIFT RCT
2020	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Radiofrequency-Induced Intravesical Chemohyperthermia for Non-Muscle-Invasive Bladder Cancer
2020	Institut national d'excellence en sante et en services sociaux (INESSS)	[Summary: investigation, treatment and follow-up algorithm - lung cancer]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Parenteral infusion pump during general hospital ward]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Glasdegib (acute myeloid leukaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020	Ontario Health	Auditory Brainstem Implantation for Adults With Neurofibromatosis 2 or Severe Inner Ear Abnormalities: A Health Technology Assessment
2020	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Vascular-targeted photodynamic therapy with padeliporfin (Tookad® Soluble)
2020	Scottish Health Technologies Group (SHTG)	Second-generation colon capsule endoscopy (CCE-2) for the detection of colorectal polyps – SHTG Recommendation
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Angioplasty with stent placement in patients with deep vein thrombosis]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivacaftor/tezacaftor/elexacaftor (cystic fibrosis, combination regimen with ivacaftor in patients aged 12 years and older [homozygous for the F508del mutation]) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020	NIHR Health Technology Assessment programme	The association between primary care quality and health-care use, costs and outcomes for people with serious mental illness: a retrospective observational study
2020	Ontario Health	Cell-Free Circulating Tumour DNA Blood Testing to Detect EGFR T790M Mutation in People With Advanced Non–Small Cell Lung Cancer: A Health Technology Assessment
2020	National Authority for Assessment and Accreditation in Healthcare (INEAS)	[Statins, lifestyle and dietary interventions to prevent cardiovascular disease]
2020	Scottish Health Technologies Group (SHTG)	Pre-treatment DPYD genetic testing for patients who are prescribed chemotherapy involving fluoropyrimidines – SHTG Assessment
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Bulevirtide (chronic hepatitis delta virus infection) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020	Scottish Health Technologies Group (SHTG)	Continuous glucose monitoring in pregnant women with type 1 diabetes – SHTG Adaptation
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Digital tomosynthesis for breast cancer]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivacaftor/tezacaftor/elexacaftor (cystic fibrosis, combination regimen with ivacaftor in patients aged 12 years and older [heterozygous for F508del and MF mutation]) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Target next generation sequencing-based gene panels in tumors of unknown origin]
2020	Agency for Care Effectiveness (ACE)	Dutasteride, tamsulosin, alfuzosin and dutasteride/tamsulosin combination for treating benign prostatic hyperplasia
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Alpelisib (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2020	Scottish Health Technologies Group (SHTG)	Endobronchial valves for lung volume reduction in patients with severe or very severe emphysema - SHTG Recommendation
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Platelet rich plasma in musculoskeletal conditions]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Entrectinib (NSCLC) - Benefit assessment according to §35a Social Code Book V]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Image-guided radiation therapy in liver and lung tumors]
2020	Agency for Care Effectiveness (ACE)	Direct-acting antiviral agents for treating genotype 1 chronic hepatitis C
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Secukinumab (plaque psoriasis in children and adolescents) - Benefit assessment according to §35a Social Code Book V]
2020	Agency for Healthcare Research and Quality (AHRQ)	No-touch modalities for disinfecting patient rooms in acute care settings: a rapid review
2020	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Health Services Research in Oncology. Part I: End-of-Life Care
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Volumetric modulated arc therapy in patients with lung cancer, prostate cancer, high-risk gliomas and tumors in head and neck]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Secukinumab (non-radiographic axial spondyloarthritis) - Benefit assessment according to §35a Social Code Book V]
2020	Institut national d'excellence en sante et en services sociaux (INESSS)	[National medical protocols and associated prescriptions, updated in August 2020: administration of drugs prescribed via an individual prescription in the event of distress for a person receiving palliative care]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Pegvaliase in phenylketonuria]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Secukinumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V]
2020	Finnish Coordinating Center for Health Technology Assessment (FinCCHTA)	Kaiku Health Service for symptom management of cancer patients
2020	Austrian Institute for Health Technology Assessment (AIHTA)	Covid-19: HSS/ Horizon Scanning Living Document (v01 April 2020) Part 1; Covid-19: HSS/ Horizon Scanning Living Document (v01 April 2020) Part 2 (Appendix)
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Digital dermatoscopy for dysplastic nevi]
2020	Agency for Care Effectiveness (ACE)	Direct-acting antiviral agents for treating genotype 2 to 6 chronic hepatitis C
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Entrectinib (solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion) - Benefit assessment according to §35a Social Code Book V]
2020	Finnish Coordinating Center for Health Technology Assessment (FinCCHTA)	Indego Exoskeleton for walking rehabilitation
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Somatostatin analogs with lutetium-177 in neuroendocrine tumors]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivacaftor (combination with ivacaftor/tezacaftor/elexacaftor, cystic fibrosis, 12 years and older, F508del mutation, homozygous) - Benefit assessment according to §35a Social Code Book V]
2020	Finnish Coordinating Center for Health Technology Assessment (FinCCHTA)	Lokomat robot for walking rehabilitation
2020	Agency for Healthcare Research and Quality (AHRQ)	Nonopioid pharmacologic treatments for chronic pain
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Dupilumab in atopic dermatitis not adequately controlled with atopical therapy]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Brigatinib (non-small cell lung cancer) - Addendum to Commission A20-42]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Ustekinumab in Crohn’s disease]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivacaftor (combination with ivacaftor/tezacaftor/elexacaftor; cystic fibrosis, 12 years and older, F508del mutation, heterozygous) - Benefit assessment according to §35a Social Code Book V]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Ozone therapy]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Information for health insurance fund members on prenatal testing]
2020	Agency for Healthcare Research and Quality (AHRQ)	Opioid treatments for chronic pain
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Radiofrequency ablation in benign bone tumors]
2020	NIHR Health Technology Assessment programme	Antimicrobial-impregnated central venous catheters for preventing neonatal bloodstream infection: the PREVAIL RCT
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Endoscopic spine surgery for disc disease and lumbar spinal stenosis]
2020	Agency for Care Effectiveness (ACE)	Pulmonary surfactant for treating respiratory distress syndrome in premature infants
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Belantamab mafodotin (multiple myeloma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020	Ontario Health	10-kHz high-frequency spinal cord stimulation for adults with chronic noncancer pain: a health technology assessment
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Endoscopic full-thickness resection of colorectal lesions]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ozanimod (multiple sclerosis) - Addendum to Commission A20-59]
2020	Ontario Health	Continual Long-Term Physiotherapy After Stroke: A Health Technology Assessment
2020	Austrian Institute for Health Technology Assessment (AIHTA)	Home-Treatment in Child and Adolescent Psychiatry: An Analysis of the Effectiveness and Possible Implementation in Austria
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Virtual colonoscopy for colorectal cancer screening in patients with diverticular disease]
2020	Agency for Care Effectiveness (ACE)	Ursodeoxycholic acid for treating primary biliary cirrhosis
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Durvalumab (small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2020	Ontario Health	Extracorporeal Membrane Oxygenation for Cardiac Indications in Adults: A Health Technology Assessment
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Intra-arterial chemotherapy for retinoblastoma]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Sofosbuvir/velpatasvir (chronic hepatitis C in children and adolescents) - Benefit assessment according to §35a Social Code Book V]
2020	Adelaide Health Technology Assessment (AHTA)	Discussion paper on pan-tumour biomarker testing to determine eligibility for targeted treatment.
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Intranasal esketamine for severe resistant major depression]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ibrutinib (CLL) - Benefit assessment according to §35a Social Code Book V]
2020	Ontario Health	5-Aminolevulinic Acid Hydrochloride (5 ALA)–Guided Surgical Resection of High-Grade Gliomas: A Health Technology Assessment
2020	Adelaide Health Technology Assessment (AHTA)	Serious adverse events associated with yellow fever vaccination
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Intrathecal baclofen pump in spastic patients]
2020	Ontario Health	Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment
2020	Adelaide Health Technology Assessment (AHTA)	Serious adverse events associated with oral cholera vaccination
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Endometrial microbiome test in assisted reproduction]
2020	Ontario Health	Genome-Wide Sequencing for Unexplained Developmental Disabilities or Multiple Congenital Anomalies: A Health Technology Assessment
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Eculizumab in the management of paroxysmal nocturnal hemoglobinuria and atypical hemolytic-uremic syndrome]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Migalastat for Fabry disease]
2020	Agency for Healthcare Research and Quality (AHRQ)	Prevention, diagnosis, and management of opioids, opioid misuse, and opioid use disorder in older adults
2020	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: safety of switching biologics and their interchangeability]
2020	Health Technology Wales (HTW)	The clinical effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis
2020	Agency for Care Effectiveness (ACE)	Intravenous proton pump inhibitors for gastric anti-secretory treatment when oral therapies are unsuitable
2020	Agency for Care Effectiveness (ACE)	Budesonide prolonged-release tablet for treating mild to moderate active ulcerative colitis
2020	Agency for Healthcare Research and Quality (AHRQ)	Resource allocation and pandemic response: an evidence synthesis to inform decision making
2020	NIHR Health Technology Assessment programme	Basic versus biofeedback-mediated intensive pelvic floor muscle training for women with urinary incontinence: the OPAL RCT
2020	Agency for Care Effectiveness (ACE)	Epoprostenol for treating pulmonary arterial hypertension
2020	Agency for Healthcare Research and Quality (AHRQ)	Retention strategies for medications for addiction treatment in adults with opioid use disorder
2020	NIHR Health Technology Assessment programme	Positron emission tomography to image cerebral neuroinflammation in ischaemic stroke: a pilot study
2020	Agency for Care Effectiveness (ACE)	Vonoprazan for treating helicobacter pylori infection
2020	Agency for Care Effectiveness (ACE)	Blinatumomab for treating relapsed or refractory B-precursor acute lymphoblastic leukaemia
2020	Agency for Care Effectiveness (ACE)	Trastuzumab for treating HER2-positive breast and gastric cancers
2020	Agency for Care Effectiveness (ACE)	Antiretroviral therapies for treating human immunodeficiency virus type 1 (HIV-1) infection
2020	Agency for Care Effectiveness (ACE)	Benralizumab, mepolizumab and omalizumab for treating severe asthma
2020	NIHR Health Technology Assessment programme	Dementia Care Mapping to reduce agitation in care home residents with dementia: the EPIC cluster RCT
2020	NIHR Health Services and Delivery Research programme	Understanding and improving experiences of care in hospital for people living with dementia, their carers and staff: three systematic reviews
2020	Agency for Care Effectiveness (ACE)	Mycophenolate mofetil for immunosuppression
2020	Agency for Healthcare Research and Quality (AHRQ)	Strategies for patient, family, and caregiver engagement
2020	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: update of the systematic review of the effects of palivizumab prophylaxis on reducing complications associated with respiratory syncytial virus infections in children]